IFNA1 and systemic lupus erythematosus: Previous reports have shown that therapeutic use IFN-a, a major type I IFN family member, can induce an SLE-like syndrome, while blocking the action of type I IFNs or their common receptor prevents immunological dysfunction and reduces tissue damage in SLE (13–16).